4.3 Letter

Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Clinical Neurology

Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped

Theo Rispens et al.

MULTIPLE SCLEROSIS JOURNAL (2012)

Article Clinical Neurology

Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal

L. Daelman et al.

MULTIPLE SCLEROSIS JOURNAL (2012)

Article Medicine, General & Internal

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

Gary Bloomgren et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)